Wendy Stock, MD

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study. Cancer. 2025 Feb 15; 131(4):e35750.
PMID: 39916320

Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.
Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia. Blood Adv. 2025 Feb 10.
PMID: 39928953

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025 Feb 06; 145(6):577-589.
PMID: 39374521

Health insurance continuity and mortality in children, adolescents, and young adults with blood cancer.
Health insurance continuity and mortality in children, adolescents, and young adults with blood cancer. J Natl Cancer Inst. 2025 Feb 01; 117(2):344-354.
PMID: 39276159

Medicaid coverage continuity is associated with lymphoma stage among children and adolescents/young adults.
Medicaid coverage continuity is associated with lymphoma stage among children and adolescents/young adults. Blood Adv. 2025 Jan 28; 9(2):280-290.
PMID: 39531060

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts.
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts. Blood Adv. 2025 Jan 24.
PMID: 39853316

Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia. 2025 Jan 13.
PMID: 39806020

CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
PMID: 39866945

DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia. Blood. 2024 Dec 27.
PMID: 39791601

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
PMID: 39093952